StockData
Elutia Inc. logo

Elutia Inc. (ELUT) stock

ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3011% below fair value
$0.82+0.00 (+0.35%)

Close on Nov 16, 2026Market cap $36.45MP/E –Yield –

Elutia r&d expenses

Research and development expenses are spending on new products and technology.

Elutia's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.80M, up 106.8% year over year. For fiscal 2025 it was $4.16M, up 38.9% from the year before. The highest annual figure on record is $9.27M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.16M+38.9%
FY2024Dec 31, 2024$3.00M-31.8%
FY2023Dec 31, 2023$4.40M-43.1%
FY2022Dec 31, 2022$7.73M-16.6%
FY2021Dec 31, 2021$9.27M+55.6%
FY2020Dec 31, 2020$5.95M+148.1%
FY2019Dec 31, 2019$2.40M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.53M+155.5%
Q1 FY2026Mar 31, 2026$1.97M+126.5%
Q4 FY2025Dec 31, 2025$1.22M+67.1%
Q3 FY2025Sep 30, 2025$1.09M+55.0%
Q2 FY2025Jun 30, 2025$989.00K-1.2%
Q1 FY2025Mar 31, 2025$871.00K-25.7%
Q4 FY2024Dec 31, 2024$727.00K-47.4%
Q3 FY2024Sep 30, 2024$702.00K+26.0%
Q2 FY2024Jun 30, 2024$1.00M+15.2%
Q1 FY2024Mar 31, 2024$1.17M-26.3%
Q4 FY2023Dec 31, 2023$1.38M-47.2%
Q3 FY2023Sep 30, 2023$557.00K-75.5%
Q2 FY2023Jun 30, 2023$869.00K-74.3%
Q1 FY2023Mar 31, 2023$1.59M-30.5%
Q2 FY2022Jun 30, 2022$2.62M+39.1%
Q1 FY2022Mar 31, 2022$2.27M+32.1%
Q4 FY2021Dec 31, 2021$3.38M+71.1%
Q3 FY2021Sep 30, 2021$2.29M+81.1%
Q2 FY2021Jun 30, 2021$1.88M+33.6%
Q1 FY2021Mar 31, 2021$1.72M+31.4%
Q4 FY2020Dec 31, 2020$1.97M+199.8%
Q3 FY2020Sep 30, 2020$1.26M+149.3%
Q2 FY2020Jun 30, 2020$1.41M–
Q1 FY2020Mar 31, 2020$1.31M–
Q4 FY2019Dec 31, 2019$658.00K–
Q3 FY2019Sep 30, 2019$507.00K–

More Elutia figures

See a number that looks wrong?